Horn & Co is a boutique firm that advises companies in the technology sector, including many in the life science and pharmaceutical industries. Its work spans high-value M&A, as well as agreements with academic institutions and governmental authorities on R&D, clinical trials, manufacturing and supply, distribution, strategic partnering, and collaboration. Lead partner Yuval Horn, who ‘consistently delivers exceptional client service’, is recognised as a leading light in the market. He recently advised a clinical stage biotechnology company on a $250m merger with a US-based private company. Keren Kanir is an acknowledged expert in corporate finance and commercial transactions relating to intellectual property. Clients note that ’their keen attention to cost-effectiveness and resource management ensures clients receive exceptional value for their investment.’
Testimonials
Collated independently by Legal 500 research team.
‘Horn & Co. demonstrated an unparalleled depth of knowledge and expertise in the acquisition and financing transactions where they represented the fund. The team's ability to navigate complex legal intricacies with precision and insight was truly impressive. They approached every aspect of the transaction with meticulous attention to detail, ensuring all elements were thoroughly analyzed and addressed.'
'The team at Horn & Co. displayed remarkable strategic thinking and negotiation prowess. They anticipated potential challenges and devised creative solutions to overcome them, always advocating fiercely for the fund’s best interests.'
Key clients
- Vascular Biogenics Ltd.
- Biosight Ltd.
Work highlights
- Advised a client on a merger transaction between Vascular Biogenics Ltd., an Israeli company traded on the Nasdaq, and Notable Labs, Inc., a US private company under which, Notable Labs will merge into a wholly owned subsidiary of VBL, with Notable surviving as a wholly owned subsidiary of VBL.
- Advised Biosight, an Israeli privately held company, which entered into an agreement in connection with areverse triangular merger with Ayala Pharmaceuticals, Inc., a US company traded on OTCQX.